InMed is a biopharmaceutical company focused on manufacturing, developing and commercializing cannabinoids. It commercializes rare cannabinoids to the health and wellness industry with flexibility across several manufacturing approaches. It is also a clinical-stage pharma company developing rare cannabinoid therapeutics.
More InMed Pharmaceuticals content >Investment summary
InMed Pharmaceuticals (INM) continues its transition from a pure-play pharma R&D firm to one also benefiting from commercial sales into the health and wellness market. Product launches of high-value, rare cannabinoids into this market should provide the majority of its revenue in the near future. Notably, InMed announced the launch of d9-THCV into B2B sales, and unlike THC, THCV is non-psychoactive and has shown indications of potential activity in combating obesity, diabetes, anxiety, Alzheimer’s disease and epilepsy. INM has also made notable advances in its pharmaceutical drug development programs, including its ongoing 755-201-EB Phase II trial and preparing for an FDA pre-investigational new drug meeting on glaucoma drug candidate INM-088. We expect to see a different InMed going forward, one that offers near-term revenue generation combined with the longer-term value of its pharma drug development programs.
Y/E Jun |
Revenue (US$m) |
EBITDA (US$m) |
PBT (US$m) |
EPS (c) |
P/E (x) |
P/CF (x) |
|---|---|---|---|---|---|---|
| 2020A | 0.0 | (9.0) | (9.0) | (172.80) | N/A | N/A |
| 2021A | 0.0 | (9.8) | (10.3) | (153.02) | N/A | N/A |
| 2022E | 1.8 | (14.6) | (14.8) | (97.62) | N/A | N/A |
| 2023E | 10.2 | (13.2) | (13.8) | (63.67) | N/A | N/A |
Industry outlook
The cannabis and cannabinoid markets are growing rapidly, reaching global sales of US$21.3bn in 2020, soaring c 50% over 2019, and are forecasted to reach US$55.9bn by 2026 according to BDSA. Furthermore, US cannabis sales are expected to be US$41bn by 2026.
Last updated on 30/06/2022Content on InMed Pharmaceuticals
Sector |
|---|
|
Healthcare
Access more Healthcare content
|
Share price graph
Balance sheet |
|
|---|---|
| Forecast net cash (US$m) | 7.4 |
| Forecast gearing ratio (%) | N/A |
Price performance
% |
1m |
3m |
12m |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||
| *% relative to local index | |||||||||||||||
Key management |
|
|---|---|
| Bruce Colwill | CFO |
| Colin Clancy | Investor relations |
| Eric Adams | President & CEO |